MyoKardia, Inc. (NASDAQ:MYOK) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, August 5th.
Other analysts have also recently issued reports about the company. TheStreet upgraded MyoKardia from a “d+” rating to a “c” rating in a report on Thursday, July 6th. BMO Capital Markets reiterated an “outperform” rating and issued a $32.00 target price on shares of MyoKardia in a report on Wednesday, May 10th. Finally, Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. MyoKardia presently has an average rating of “Buy” and an average target price of $37.60.
Shares of MyoKardia (NASDAQ:MYOK) traded down 7.184% during mid-day trading on Friday, hitting $40.375. 942,622 shares of the company were exchanged. MyoKardia has a 12-month low of $10.55 and a 12-month high of $44.28. The company’s market capitalization is $1.27 billion. The firm has a 50 day moving average of $21.23 and a 200 day moving average of $15.10.
In other MyoKardia news, insider Joseph Lambing sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $40.00, for a total transaction of $200,000.00. Following the transaction, the insider now directly owns 104,718 shares in the company, valued at approximately $4,188,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Wendy L. Yarno bought 1,408 shares of the stock in a transaction dated Monday, August 14th. The shares were purchased at an average cost of $35.50 per share, for a total transaction of $49,984.00. Following the completion of the transaction, the director now directly owns 1,408 shares of the company’s stock, valued at $49,984. The disclosure for this purchase can be found here. Insiders have sold a total of 72,288 shares of company stock worth $1,641,236 over the last 90 days. Company insiders own 46.10% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its position in shares of MyoKardia by 36.3% in the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after buying an additional 2,591 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in shares of MyoKardia during the first quarter worth $136,000. Alliancebernstein L.P. purchased a new position in shares of MyoKardia during the second quarter worth $148,000. State of Wisconsin Investment Board purchased a new position in shares of MyoKardia during the second quarter worth $157,000. Finally, Daiwa SB Investments Ltd. purchased a new position in shares of MyoKardia during the first quarter worth $170,000. 47.63% of the stock is currently owned by institutional investors.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
What are top analysts saying about MyoKardia Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MyoKardia Inc. and related companies.